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Changes in glomerular epithelial cells induced by FGF2 and
FGF2 neutralizing antibody in puromycin aminonucleoside
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Changes in glomerular epithelial cells induced by FGF2 and FGF2
neutralizing antibody in puromycin aminonucleoside nephropathy. In the
present study, two series of experiments were done with PAN nephropathy
rats given fibroblast growth factor 2 (FGF2) or FGF2 neutralizing
antibodies. In the first series of experiments, a dose of 10 jg of FGF2
(FGF2 group), 40 jrg of an FGF2 neutralizing antibody (Anti-FGF2
group) or an equal volume of physiological saline (Control group) was
administered for four days after PAN injection. Urinary protein increased
more in the FGF2 group than in the other two groups. PCNA (+)
glomerular cells were found in decreasing order in groups FGF2, Control
and Anti-FGF2. Most of the PCNA (+) cells were podocytes and
epithelial cells of Bowman's capsule. Staining for desniin, a marker of
podocyte injury, was significantly reduced in the Anti-FGF2 group.
Glomerular adhesive lesions were found in decreasing order in groups
FGF2, Control and Anti-FGF2. The second series of experiments was
designed to study the effects of FGF2 neutralizing antibody (40 jg for 5
days after PAN injection, in MoAb group) on severely damaged podocytes
caused by repeated (two courses) injections in the PAN nephropathy rats.
The results were the same as those in series 1. An increase in urinary
protein excretion was observed in both groups, but on the 40th day, the
level of proteinuria in the MoAb group decreased abruptly. It was
observed that the MoAb group had few adhesive glomeruli compared to
the IgG group (administration of mouse IgG) and the PCNA (+)
epithelial cells of Bowman's capsule were also few. It was supposed that
FGF2 would promote the formation of adhesive lesions by stimulating the
proliferation of podocytes and epithelial cells of Bowman's capsule.
Additionally, FGF2 itself was thought to impair podocytes because of the
increasing desmin score and proteinuria.
The visceral epithelial cells or podocytes are the most differen-
tiated cell type of the renal glomerulus. Under pathological
conditions, unique changes occur in the cell architecture of
podocytes. Among cells forming the glomerulus, podocytes do not
readily proliferate under normal conditions. 1-lowever, epithelial
cells of Bowman's capsule (which have the same origin as
podocytes during the embryonal period) show a comparatively
higher replicative potential [1, 2]. Also, previous studies using rats
with diabetic ncphropathy (31, unilateral and subtotal nephrec-
tomy [4, 5] and anti-GBM nephritis [6] showed neither evidence
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for podcoyte nuclear division nor an increase in the number of
podoyctes per glomerular cross section. When podocytes are
injured, they become detached from the glomerular basement
membrane (GBM). Detachment of podocytes from the GBM at
such sites, allows the epithelial cells of Bowman's capsule access
to the GBM. This lesion is defined as early glomerular adhesion
[7]. Such an early adhesion is generally not associated with
sclerotic lesions in the corresponding tuft area. These lesions
develop later. Proliferation of epithelial cells of Bowman's capsule
is observed at the site of adhesion and is involved in their
formation [4, 5, 8—12]. Therefore, it may be important that the
factor should be mitogen for epithelial cells of Bowman's capsule
in the early adhesive glomerular lesions. However, there have
been few studies on the growth factors affecting proliferation of
podocytes and epithelial cells of Bowman's capsule. It has been
reported that fibroblast growth factor 2 (FGF2) has a proliferative
effect on cultured glomerular epithelial cells [13]. Recent studies
have shown that treatment of rats with FGF2 induces conspicuous
structural changes in podoeytes such as cell hypertrophy and
widespread vacuolar formation. Segmental glomerulosclerosis
with adhesive lesions was detected in these rats [14, 151. We
previously reported that the expression of FGF2 and FGF recep-
tors was detected in damaged podocytes and epithelial cells of
Bowman's capsule of rats with puromycin aminonucleoside
(PAN) nephropathy [16]. Floege et al [17] suggest that released
FGF2 from sublethal mesangial cell injury may be an important
step in the initiation of mesangial proliferative glomerulonephri-
tis. Therefore, we investigated the role of FGF2 in glomerular
epithelial cell injury. In the present study, two series of experi-
ments were done with PAN nephropathy rats given FGF2 and
FGF2 neutralizing antibodies. The first series of experiments was
intended to clarify the effect of FGF2 and FGF2 neutralizing
antibodies on rats with PAN nephropathy after the induction of
glomerular epithelial cell damage. The second series of experi-
ments was designed to study the effect of FGF2 neutralizing
antibody on more severely damaged glomerular epithelial cells of
rats by repeated injection with PAN.
Methods
Animals
Male Wistar strain rats (Clea Japan Co., Osaka, Japan) weigh-
ing 110 g were used. The animals were housed in metabolic cages
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Series. 1
day—0 1 2 3 4 5 6 7 8 9 10
FGF2 group
(N=5)
Anti-FGF2 group
(N=5)
Control group
< <(N=5)
MoAb group
(N=5)
Mouse lgG group
(N=5)
and given food and water ad libitum. All surgery and all infusions
were performed under general anesthesia with ether and addi-
tional injections of phenobarbital when necessary.
Series I experiments
PAN nephropathy was produced by intraperitoneal injections
of PAN (1,5 mg/I 00 g body weight/day; Sigma Chemical Co., St.
25 26 27 28 29 30
Louis, MO, USA) into rats for five days [181. After PANinjection,
10 pg of recombinant FGF2 (Intergen Co., NY, USA) (N = 5,
FGF2 group), 40 jxg of FGF2-neutralizing antibody (clone 3H3)
(N 5, Anti-FGF2 group) or the equal volume of physiological
saline (N = 5, Control group) was injected for four days into the
tail vein, and the animals were sacrificed on the 30th day after the
start of PAN administration (Fig. 1). Previous studies reported
PAN 1.5 mg/i00 g body wt
intraperitoneal injection
I .11
I I I I I I I
Sacrifice
Sacrifice
4— Sacrifice
Series. 2
PAN 1.5 mg/i 00 g body wt PAN 1.5 mg/i 00 g body wt
.11111 11111
I I I I I I I I I I I I I I I
day— 0 1 2 3 4 5 6 7 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
Sacrifice
t t t t t Sacrifice
Fig. 1. Experimental design. Outline of the experimental design (series I and 2) showing various groups of rats studied. Symbols arc: ('fl') 10 pg FGF2;() 40 pg neutralizing antibody of FGF2; (X) saline solution; (1) 40 pg mouse IgG.
Fig. 2. Normal Wistar rats were received 10 pg
of recombinant FGF2 once a day for a period of
four days. No morphological abnormality of the
glomerulus was found. PAS x400.
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Fig. 3. Daily urinaly protein excretion of PAN
rats following infusion of MoAb (Anti-FGF2
group), FGF2 (FGF2 group), saline solution
(Control group). All values are expressed as the
mean SD. It is apparent that significant
changes in the secretion of urinary protein took
place on the 16th day, which increased more in
the FGF2 group (LII, N = 5) than in the other
two groups. When compared, the level of
urinary protein in the Anti-FGF2 group (,
N = 5) was found to be lower than that in the
Control group (H, N = 5) on the 21st day.
*p < FGF2 group versus Anti-FGF2, **p
<0.01, Control groups. AAntiFGF2 group
versus Control group.
that clone 3H3 has an immuno-neutralizing activity for FGF2-
induced proliferation of human umbilical vein endothelial cells
[19]. Also, our study showed inhibition of FGF2-induced prolif-
eration of cultured mesangial cell (data not shown).
Series 2 experiments
More frequent sclerotic lesions with adhesion were produced by
intraperitoneal injection of 1.5 mg/l00 g body wt of PAN into rats
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Fig. 4. A. There arc slight inoiphological abnormalities of the glomerulus oft/ic Contra/group rats. Cytoplasmic granules that a stained positive with PAS
are present in podocytes (arrowhead). (PAS X400). B. Cytoplasniic granules that stained positive with PAS are present in podocytcs (arrowhead);
hypcrtrophic and proliferative epithelial cells of Bowman's capsule (arrowhcads) can he seen in the FGF2 group rats (PAS X400). C, D. The
proliferation of glomerular epithelial cells can be seen in the adhesive lesions in the FGF2 group rats (PAS X4tJ0).
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ture. After washing in phosphate-buffer saline, bound antibodies
were detected using the ABC kit (Vector Co., Barlingame, USA).
The bound antibodies were detected using 3,3-diaminobenzidine
tetrahydrochioride (DAB) in Tris-buffer saline containing 0.02%
hydrogen peroxide for 5 to 10 minutes. The number of PCNA (+)
and ED1 (+) cells along with 50 glomeruli were observed.
Glomerular desmin expression was evaluated semiquantitatively
in four grades: Grade 0 (0 to 5%), Grade 1 (5 to 25%), Grade 2
(25 to 75%), Grade 4 (> 75%), depending on the appearance of
positive staining.
Control study. Normal Wistar strain rats were divided into four
groups, which received either 10 g of recombinant FGF2 (N =2;
Intergen Co., NY, USA), 40 g of FGF2-neutralizing antibody
(N = 2; clone 3H3), the equal volume of mouse IgG (N = 2), or
the equal volume of physiological saline (N = 2), respectively,
once a day for a period of four days. Every day 24-hour urinary
protein excretion was checked. Twenty-five days after the first day
of injection, these rats were sacrificed. The four groups had no
significant difference in the 24-hr urinary protein excretion and
PCNA (+) glomerular cells. Adhesive glomeruli and desmin
stained glomeruli were not detected (Fig. 2).
Statistical analysis
All values were expressed as the mean so. Comparisons be-
tween groups were made using the Student's t-test or Welch's
t-test.
for five consecutive days [18], on the first and 25th days, respec-
tively. After the last PAN injection, 40 j.g of FGF2-neutralizing
antibody (clone 3H3; N = 5, MoAb group) or an equal volume of
mouse IgG (N = 5, Group IgG) was injected for five days into the
tail vein, and the animals were sacrificed on the 40th day after the
start of PAN administration (Fig. 1).
Level of urinary protein
Daily urinary protein levels were determined by the Kingsbury-
Clark's method.
Renal morphology and immunohistochemistiy. Rats were per-
fused with 4% paraformaldehyde (PFA) via the left ventricle, and
both kidneys were fixed. After dehydration, the kidneys were
embedded in paraffin and thin sections were prepared. After
deparaffinization, periodic acid-Schiff (PAS) or periodic acid
methenamine silver (PAM) staining was performed on these
sections, and the number of adhesive glomeruli per 100 glomeruli
was counted. Even if there was more than one adhesive lesion in
a glomerulus, they were counted as a single adhesive glomerulus.
The following antibodies were used for immunoperoxidase stain-
ing of 4% PFA fixed paraffin sections: PC1O (a cell proliferation
marker; Dako Co., Denmark), which is a monoclonal antibody to
the proliferating cell nuclear antigen (PCNA), EDI (Serotec,
Oxford, UK), a monoclonal antibody to monocyte/macrophage,
which checked presence of these cells in glomeruli, and D33
(Dako), a monoclonal antibody to desmin that is detected in
podocyte injury [20]. The sections were treated with 0.3% hydro-
gen peroxidase in methanol for 30 minutes at room temperature
to inactivate endogenous peroxidase. Then they were immersed in
non-immunohorse serum for 30 minutes, washed in 0.02 M
phosphate-buffer saline (pH 7.2), and were made to react with
primary monoclonal antibodies for two hours at room tempera-
Results
Series 1 experiments
Level of urinary protein. Our previous study showed that the
24-hr urinary protein excretion of normal adult rats was less than
10 mg. Onset of massive proteinuria was noted ten days after the
intraperitoneal injection of PAN. This proteinuria gradually in-
creased. Especially significant differences in the increase of uri-
nary protein were observed on the 16th day, being more in group
F than in the other two groups. When compared, the level of
urinary protein in group M was found to be less than that of group
C on the 21st day (Fig. 3).
Renal morphology and immunohistochemistty. The morphologi-
cal changes of podocytes (such as cytoplasmic vacuolar formation
and accumulation of PAS positive materials) were detected more
frequently in the FGF2 group. Other morphological changes in
the glomeruli consisted of hypertrophy and proliferation of epi-
thelial cells of Bowman's capsule. Also, a mitotic figure of the
epithelial cells of Bowman's capsule was easily detected at the site
of glomerular adhesive lesions (Fig. 4). The number of adhesive
glomeruli was higher in the FGF2 group and lower in the
Anti-FGF2 group compared to the Control group (Fig. 5).
Adhesive lesions appeared to be randomly distributed in the three
groups. The PCNA (+) glomerular cells were mainly podocytes,
and the number of epithelial cells of Bowman's capsule in the
FGF2 group was higher than in the other two groups (Fig. 6A).
There was no difference in the number of EDI (+) cells in
glonieruli in among the three groups. They were found exclusively
in the mesangial areas and capillary lumens (Fig. 6B). These
epithelial cells of Bowman's capsule were detected not only in
adhesive lesions, but also in other places of the Bowman's capsule.
The desmin score of glomeruli was lower in the Anti-FGF2 group
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Fig. 5. The number of adhesive glomeruli per 100 glomeruli. The number of
adhesive glomeruli is larger in the FGF2 group and smaller in the
Anti-FGF2 group compared with the Control group. Data arc mean SI).
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Fig. 6. A. PCNA (+) cells are mainly podocytes
(arrows) and epithelial cells of Bowman c capsule
(arrowheads). Asterisk, site of adhesive lesion;
BC, Bowman's capsule (X1000). B. Site of
adhesive lesion (asterisks) showing no
participation of ED1 (+) cells, however, ED1
(+) cells (arrowhead) are present in the
periglomerular interstitium (>< 1000).
than in the other two groups; however, no significant difference
was noted between the Control and FGF2 groups (Table 1).
Series 2 experiments
Level of urinaty protein. An increase in urinary protein excretion
was observed in both groups, hut on the 40th day, the level of
proteinuria in the MoAb group decreased abruptly (Fig. 7).
Renal morphology and iinrnunohistochemisiiy. In the same way
as in series 1, the MoAb group had fewer adhesive glomeruli than
the IgG group (Figs. 8 and 9). The frequency of PCNA (+)
glomerular cells and epithelial cells of Bowman's capsule was also
higher in the MoAb group than in the lgG group. However, there
was no difference in the number of EDI (+) cells. Also, the
desmin score of glomeruli was lower in the MoAb group than in
the IgG group (Fig. bA, B and Table 2).
Discussion
This study showed that intravenous injection of FGF2 markedly
increased the glomerular podocyte injury and proliferation of
epithelial cells of Bowman's capsule in PAN nephropathy. The
previous study reported that FGF2 rapidly cleared up from serum
after intravenous injections and was deposited to a greater extent
in solid organs than in blood vessel walls. Deposition was greatest
in Ihe kidney followed by the liver, and spleen and was substan-
tially smaller in the heart and lung [21]. The present data as well
as recent in vivo and in vitro findings suggested that FGF2 might
be one of the factors involved. FGF is a member of a family of
polypcptidc growth factors (of which nine have been identified to
date), which in turn are capable of being hound to any of the
components of the tyrosine kinase receptors (4 of which have
Control Anti-FGF FGF 2
group 2 group group(N=5) (N=5) (N=5) -
MoAb group(N=5) IgG group(N=5)
PCNA(+) glomerular cells
PCNA(+) epithelial cells of
Bowman's capsule
186.6 5.7 253.8 34.5
25.2 10.8 49.3 15.8
ED 1(+) cells
Desmin score
2.6 1.1 2.2 0.8
101.0 2.9 119.8 11.2
7.0 0.7 1.6 0.9 2.2 0.8 The number of PCNA (+) glomerular cells, epithelial cells of Bowman's
capsule, EDI (+) cells and desmin score per 50 glomeruli.
91.8 12.1 21.3 3.5 87.0 21.0 Data are means SD.
"P<0.05
h
the collecting ducts and distal tubules [25, 26]. FGF2 expression
was observed in podocytes and epithelial cells of Bowman's
capsule of PAN nephropathy rats [16]. FGF2 emits no signal
before secretion, so the mechanism of its release is unclear. In cell
injury, FGF2 is released from its cytosolic storage sites through
plasma membrane disruption [27]. Extracellularly, it is bound to
hcparan sulfate proteoglycans where it may be released by
heparin and heparitinases [28]. Disruption of the cytoplasm of
damaged podocytes was observed under an electron microscope
(data not shown), suggesting that FGF2 may have a paracrine
influence on the proliferation of epithelial cells of Bowman's
capsule. Since FGF2 mRNA is present in the epithelial cells of
Bowman's capsule, an autocrine influence cannot be denied.
Although no proliferative action of FGF2 is observed in normal
glomeruli, such an effect on damaged mesangial cells has already
been reported [29].
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Table 1. Histological evaluation of series 1 study
10 20 30 40
Fig. 7. Daily urinary protein excretion of PAN
rats fbI/owing infusion of either MoAb (, MoAb
group) or mouse IgG (, IgG group). All values
are expressed as the mean si. Tt is apparent
that significant changes in the secretion of
urinary protein took place on the 40th day.
*P < 0.05.
Table 2. Histological evaluation of series 2 study
65.2 27.3 26.2 12.1 175.0 57.2PCNA(+) glomerular
cells
PCNA(+) epithelial cells
of Bowman's capsule
ED 1(+) cells
Desmin score
7.6 2.5 4.1 1.2 35.2 12.3
The number of PCNA (+) glomerular cells, epithelial cells of Bowman's
capsule, EDI (+) cells and desmin score per 50 glomeruli.
Data arc means SD.
ap < 0.05; P < 0.01
been identified to date) [22]. One of these growth factors, FGF2,
has received particular attention as a potential mediator of
glomerular injury. The role of FGF2 in in vivo models of wound
healing, angiogenesis, and cardiovascular development has been
demonstrated. A number of glomerular cell types, such as mes-
angial cells [23], endothelial cells [24] and visceral epithelial cells
[13], can be stimulated to proliferate in response to exposure to
FGF2. This implies that each of these cell types bears specific
FOF receptors. In our previous studies, FGF2 protein was found
in the normal rat glomeruli, but its mRNA was not detected.
However, FGFR protein and FGFR1-4 mRNAs were present in
I
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Fig. 8. It is observed that the MoAb group (B)
has fewer adhesive glomeruli (arrows) than the
IgG group (A). (PAM X200).
In the present study, many PCNA (+) podocytes and epithelial
cells of Bowman's capsule were observed when FGF2 was injected
following PAN, and the PCNA (+) cells decreased when an
FGF2-neutralizing antibody was injected. No monoeyte/maero-
phage was found in adhesive lesions either. This result was
considered to be related to FGFR mRNA expression by podo-
eytes and epithelial cells of Bowman's capsule, suggesting an in
situ hybridization [17]. However, further detailed studies are
necessary for more clear and detailed understanding of the role of
FGFRI-4. PCNA (+) podoeytes showed morphological abnor-
malities, such as vacuolization and accumulation of PAS-positive
materials in the cytoplasm. Since the desmin score, (a marker for
damaged podocytes), was reduced by administration of the FGF2-
neutralizing antibody, there is a possibility that FGF2 may play a
role in podocytc damage. Some evidence suggests that nuclear
division in podocytcs was not followed by complete cell division.
Kriz et al recently did not observe an increase in the absolute
number of podocytes despite nuclear division in podocytcs after
long-term, high-dose administration of FGF2 to rats [15]. The
FGF2-induced podoeyte changes had severe structural abnormal-
ities, which probably showed the important role of podocytes in
maintaining the glomerular permcsclectivity [30]. This indicated
that FGF2 injection also increased the occurrence of protcinuria.
Also, it has been suggested that FGF2 might become relevant in
those podoeytes that have more sensitivity to FGF2 due to an
up-regulation of FGF2 receptors. FGF2 did not induce prolifer-
ation of glomerular cells in normal rats. Furthermore, Floege et al
[31, 321 reported that rats receiving a subnephrotogenic dose of
Heymann serum develop glomeruloselerosis in the additional
treatment with small doses of FGF2. Recently the development of
308 Sasaki Ct al: FGF2 in glomerular epithelial cell injuRy
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Fig. 10. Desmin score of glomendi (arrows) was lower in the MoAb group (A, C) than in the JgG group (B, D). A, B x200, C, D X400.
HIV-associated nephropathy has been linked to FGF2 [33]. indicate that FGF2 released from injured podocytes may act
HW-nephropathy consists of rapidly progressing focal glomeru- synergistically with other damaging mechanisms.
loscierosis characterized by severe podocyte lesions [34]. These Moreover, in vitro data from a previous study showed that
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FGF2 released from injured podocytes may act on the opposite
epithelial cells of Bowman's capsule to induce their proliferation.
Since FGF2 administration caused an increase in PCNA (+)
epithelial cells of Bowman's capsule whereas administration of
neutralizing antibody inhibited the formation of adhesive glomer-
uli, proliferation of epithelial cells of Bowman's capsule may be
suggestive of involvement of FGF2 in the formation of adhesive
lesions. From these results, it can be assumed that FGF2 has a
complex role in podocyte injury and induces subsequent responses
in epithelial cells of Bowman's capsule.
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